Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

Chehelgerdi, Mohammad; Chehelgerdi, Matin; Allela, Omer Qutaiba B.; Pecho, Renzon Daniel Cosme; Jayasankar, Narayanan; Rao, Devendra Pratap; Thamaraikani, Tamilanban; Vasanthan, Manimaran; Viktor, Patrik; Lakshmaiya, Natrayan; Saadh, Mohamed J.; Amajd, Ayesha; Abo-Zaid, Mabrouk A.; Castillo-Acobo, Roxana Yolanda; Ismail, Ahmed H.; Amin, Ali H.; Akhavan-Sigari, Reza

doi:10.1186/s12943-023-01865-0

Molecular Cancer

Table 15 Nanocarrier-based personalized cancer therapy

From: Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

Molecular Biomarker	Treatment Strategy	Clinical Outcome	Cost-effectiveness	References
EGFR mutation	Erlotinib-loaded nanocarriers targeted to EGFR	Partial response with improved quality of life	High	[297]
BRCA1 mutation	Poly(ADP-ribose) polymerase (PARP) inhibitor-loaded nanocarriers targeted to BRCA1	Complete response with no adverse events	Moderate	[190]
KRAS mutation	Gemcitabine-loaded nanocarriers targeted to tumor stroma	Stable disease with improved pain control	Low	[234] [298]
BRAF mutation	Vemurafenib-loaded nanocarriers targeted to BRAF	Complete response with skin rash	High	[299]
KRAS wild-type	Irinotecan-loaded nanocarriers targeted to CD44v6	Stable disease with improved quality of life	Moderate	[218]
BRCA2 mutation	Doxorubicin-loaded nanocarriers targeted to BRCA2	Partial response with improved pain control	High	[300]
HER2 overexpression	Trastuzumab-loaded nanocarriers targeted to HER2	Complete response with no adverse events	High	[301]
KRAS mutation	Paclitaxel-loaded nanocarriers targeted to tumor stroma	Stable disease with improved appetite	Low	[302]
AR overexpression	Enzalutamide-loaded nanocarriers targeted to AR	Complete response with no adverse events	High	[303]
KRAS mutation	Gemcitabine-loaded nanocarriers targeted to tumor stroma	Partial response with improved appetite	Low	[234] [220]
HER2 overexpression	Trastuzumab-loaded nanocarriers targeted to HER2	Complete response with no adverse events	High	[221] [301]
BRAF mutation	Cetuximab-loaded nanocarriers targeted to EGFR	Partial response with improved quality of life	Moderate	[304]
BRCA1 mutation	Olaparib-loaded nanocarriers targeted to BRCA1	Partial response with improved pain control	High	[193]
ALK rearrangement	Crizotinib-loaded nanocarriers targeted to ALK	Complete response with improved appetite	High	[305]
KRAS mutation	5-Fluorouracil-loaded nanocarriers targeted to tumor stroma	Stable disease with improved quality of life	Low	[95]
HER2 overexpression	Lapatinib-loaded nanocarriers targeted to HER2	Partial response with improved appetite	Moderate	[306]
BRAF mutation	Dabrafenib-loaded nanocarriers targeted to BRAF	Complete response with skin rash	High	[267]
AR overexpression	Abiraterone-loaded nanocarriers targeted to AR	Partial response with improved quality of life	High	[307] [219]
PARP1 overexpression	Olaparib-loaded nanocarriers targeted to PARP1	Partial response with no adverse events	High	[308]

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com